CFB
TSVT

Cullen/Frost Bankers’s 2seventy bio TSVT Stock Holding History

Cullen/Frost Bankers’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3
Closed -$9 – 1474
2024
Q4 		$9 Buy
+3
New +$12 ﹤0.01% 1337

Other funds holding TSVT

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Cullen/Frost Bankers's TSVT Position: Q1 2025 in Review

Cullen/Frost Bankers sold out of 2seventy bio (TSVT) in Q1 2025, closing a stake of 3 shares — an estimated $9 sold.

Cullen/Frost Bankers first reported a position in TSVT in Q4 2024 and held it in 1 quarter. The position peaked at $9 in Q4 2024. 139 funds tracked by Wall St. Rank hold TSVT as of Q1 2025.

  • Cullen/Frost Bankers reported no remaining 2seventy bio position as of Q1 2025 after selling out during the quarter.
  • Cullen/Frost Bankers sold 3 2seventy bio shares in Q1 2025, an estimated $9.
  • Cullen/Frost Bankers first reported a position in 2seventy bio in Q4 2024 and held it in 1 quarter.
  • Cullen/Frost Bankers's 2seventy bio position peaked at $9 in Q4 2024.
  • 139 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2025.

Based on Cullen/Frost Bankers's 13F filing for Q1 2025, filed 2 May 2025.